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ABSTRACT 
Floating Drug delivery systems are designed to prolong the gastric residence time after oral administration. Dicycloverine is used for 
irritable bowel syndrome, abdominal pain, motion sickness and other conditions. Dicycloverine works by relieving smooth muscle 
spasms of the gastrointestinal tract. It is more soluble in water, alcohol and chloroform and slightly soluble in ether. Precipitation of 
the drug occurs in the intestine, which adversely affects the absorption in the lower sections of the intestine. So there is a need for 
systems that reside in the stomach over a relatively long period and release the active compound in a sustained manner. The aim of 
the present study was to develop a delivery system wherein the retention of Dicycloverine could be achieved for increasing local 
action in the gastric region against irritable bowel disease (IBD) and GIT spasms with the development of sodium alginate floating 
beads containing Dicycloverine. Various formulations (FB1- FB7) of floating beads of Dicycloverine were developed using different 
concentrations of polymers like Ethyl cellulose, PVP, HPMC etc. The beads were prepared by Ionotropic gelation method using 
calcium chloride as a cross-linking agent. Floating beads were characterized by polymer compatibility by using FT-IR, DSC & 
Calibration. The prepared beads were evaluated for particle size, surface morphology, buoyancy, actual drug content, and entrapment 
efficiency in vitro drug release and stability studies. Finally batch FB1 is concluded as optimum formulation. 
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1. INTRODUCTION 
Floating drug delivery system (FDDS) promises to be a 
potential approach for gastric retention. The controlled 
gastric retention of solid dosage forms may be achieved 
by the mechanisms of mucoadhesion, flotation, 
sedimentation, expansion, modified shape systems, or by 
the simultaneous administration of pharmacological 
agents that delay gastric emptying. Several approaches 
are currently used to prolong gastric retention time
1
. 
These include floating drug delivery systems, also 
known as hydro dynamically balanced systems, swelling 
and expanding systems, polymeric bio adhesive systems, 
modified-shape systems, high-density systems, and other 
delayed gastric emptying devices. Various gastro 
retentive techniques were used, like floating, swelling, 
high density, and bio-adhesive system. Out of these 
floating system have been explored to increase the 
gastro-retention of dosage forms
2, 3
. 
Calcium alginate gel beads have been developed in 
recent years as a unique vehicle for drug delivery 
system. Various categories of drug have been 
encapsulated such as non-steroidal anti-inflammatory 
drugs, enzymes, peptides/proteins, and acid labile 
drugs
4
.  
Dicycloverine was selected as a model drug for 
incorporation in calcium alginate beads. Dicycloverine is 
used for irritable bowel syndrome, abdominal pain, 
motion sickness and other conditions. Dicycloverine 
works by relieving smooth muscle spasms of the 
gastrointestinal tract. It is more soluble in water, alcohol 
and chloroform and slightly soluble in ether. The beads 
were evaluated with respect to micromeretic properties, 
Setia et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(4):346-355         
ISSN: 2250-1177                                                                             [347]                                                                             CODEN (USA): JDDTAO 
 
floating property, drug content, entrapment and 
encapsulation efficiency, in vitro drug release.  
In the present investigation, a controlled release 
formulation of Dicycloverine capable of providing 
detectable blood levels over 10-12 hrs
5
 was formulated. 
The polymer used was sodium alginate which is an 
inexpensive and nontoxic. Sodium alginate has been 
used as thickening and gelling agent. Hydroxy propyl 
methylcellulose (K100M), ethyl cellulose and PVP were 
also used to achieve a controlled drug release
6, 7, 8
. 
2. MATERIAL AND METHODOLOGY 
 
 
Table 1: Chemicals used in research work 
S.NO     Chemicals Source 
1.  Dicycloverine  Agron Remedies Pvt. Ltd Kashipur, India. 
2.  Ethyl cellulose Agron Remedies Pvt. Ltd Kashipur, India. 
3.  Polyvinyl Pyrolidine LOBA Chemie Pvt. Ltd. Mumbai 
4.  Hydroxy propyl methyl cellulose Agron Remedies Pvt. Ltd Kashipur, India. 
5.  Sodium Alginate Classic Business Organisation Kashipur, India. 
6.  Calcium chloride Pallav Chemicals & Solvents Pvt. Ltd. Boisar 
7.  Calcium Carbonate Pallav Chemicals & Solvents Pvt. Ltd. Boisar 
8.  Sodium Alginate Babu Genu Road, Mumbai 
 
Table 2: Equipments used in research work 
S.NO Equipment Company 
1.  Single pan Electronic Balance Sigma-200/A Deluxe, Sen Shine Balance Works, Varanasi, India 
2.  Magnetic stirrer Biocraft, Gwalior, M.P.India 
3.  pH – Meter VSI-1B,VSI electronic Chandigarh, India 
4.  Hot – air oven Biocraft, Gwalior, M.P., India 
5.  UV/ Vis Spectrophotometer Lasani 
6.  Mechanical Shaker Jyoti Industries, Gwalior, M.P., India 
7.  FTIR Spectrophotometer Perkin Elmer, BX, UK 
8.  Dissolution Apparatus(USP XXIV, type I) Electrolab, Mumbai, India 
9.  Dessicator Biocraft, Gwalior, M.P., India 
10.  Scanning Electron Microscope  JEOL, Japan 
11.  DSC instrument  NETZSCH, DSC-204 F1 PHOENIX 
 
2.1. Preformulation studies9: 
Preformulation testing is the first step in the rational 
development of dosage forms of a drug. It can be 
defined as an investigation of physical and chemical 
properties of drug substance, alone and when combined 
with excipients in order to develop stable, safe and 
effective dosage form. The overall objective of 
preformulation testing is to generate information useful 
to the formulator in developing stable and bioavailable 
dosage forms, which can be mass produced. A thorough 
understanding of physicochemical properties may 
ultimately provide a rationale for formulation design or 
support the need for molecular modification or merely 
confirm that there are no significant barriers to the 
compounds development
10
. The goals of the program 
therefore are: 
1. To establish the necessary physicochemical 
characteristics of a new drug substance. 
2. To determine its kinetic release rate profile. 
3. To establish its compatibility with different 
excipients. 
Hence, preformulation studies of the obtained sample of 
drug include color, tests, solubility analysis, melting 
point determination and compatibility studies. 
2.1.1. Physical Appearance:  
The drug was observed visually for the color and 
appearance, whether amorphous or crystalline. 
2.1.2. Angle of Repose: 
Angle of repose helps to evaluate powder flowability by 
assessing inter-particulate friction. In general, the higher 
is the angle of repose poor is the flowability of powde
11
. 
The angle of repose of each powder blend was 
determined by glass funnel method, using following 
equation, 
tan θ = h/r 
Here, θ= Angle of Repose 
h= Height of the pile 
r = Radius of the cone made by powder blend 
Table 3: Relation between angle of repose and 
flowability 
Angle of Repose Flowability 
<20 Excellent 
20-30 Good 
30-34 Passable 
>40 Very poor 
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2.1.3. Bulk Density: 
It is ratio of mass to bulk volume. Bulk density may 
influence dissolution and other properties and depends 
on the particle size, shape and tendency of particles to 
adhere together. Bulk density of formulated beads was 
determined by taking a known mass of beads in a 5 ml 
graduated measuring cylinder. The cylinder was dropped 
three times from a height of one inch at an interval of 
two seconds. The bulk density was calculated by 
following equation, 
ρb= M/Vb 
Where, ρb= Bulk density 
M = Weight of the Powder 
Vb = Bulk Volume 
 
2.1.4. Tapped density: 
Tapped density helps to determine packing geometry 
and flowability. Tapped density is the volume of powder 
determined by tapping using measuring cylinder 
containing weighed amount of sample. Tapped density 
of beads was calculated by following equation, 
ρt =   M/Vt 
Where, ρt=Tapped density 
M = Weight of the powder 
Vt =   Tapped powder 
2.1.5. Carr’s compressibility index: This is an 
important property in maintaining uniform weight. It is 
calculated using following Equation, 
 
               
                –             
              
 x 100 
Table 4: Carr’s compressibility index 
% Compressibility Flow Description 
5-15 Excellent(free flowing granules) 
12-16 Good (free flowing powdered 
granules) 
18-21 Fair (powdered granules) 
23-28 Poor (very fluid powder) 
28-35 Poor (fluid cohesive powder) 
35-38 Very poor (fluid cohesive powder) 
>40 Extremely poor (cohesive powder) 
 
2.1.6. Hausner’s ratio: 
Hausner’s ratio less than 1.25 indicates good flow and 
greater than 1.5 indicates poor flow whereas between 
1.25 and 1.5 indicates glidant normally improves flow. 
Hausner’s ratio can be calculated by formula, 
                 
              
            
 
2.1.7. Solubility analysis 
Solubility of Dicycloverine in water was determined at 
37
0
C.10gm of Dicycloverine was transferred in a series 
of different solvents having volume 10 ml in different 
test tubes
12
. These test tubes were shaken by a 
mechanical shaker for 2 hours under constant 
temperature. Solution was filtered by Whatman filter 
paper and the clear filtrate was assayed spectro-
photometrically at 210 nm against blank solution
13
. 
Available literature shows that adsorption to Filter II 
(Whatman Filter) was much lower and in most cases 
negligible. 
2.1.8. Melting point determination 
Melting point determination of the obtained sample was 
done because it is a good first indicationof purity of the 
sample sincethe presence of relatively small amount of 
impurity can be detected by a lowering as well as 
widening in the melting point range
14
. Melting point of 
Dicycloverine was determined by using Melting Point 
Apparatus, the drug filled (sample amount) in a capillary 
tube whose one end is sealed with the flame was placed 
in the pockets of apparatus accompanied with 
thermometer. The heating was started and the point at 
which drug start melting was noted and the melting point 
of drug were found to be 160- 163
0
C. 
2.1.9. Partition coefficient  
The partition coefficient is defined as the ratio of 
unionized drug distributed between the organic and 
aqueous phase at equilibrium. For a drug delivery 
system, lipophilic/hydrophilic balance has been shown 
to be a contributing factor for rate and extent of drug 
absorption. Partition coefficient provides a means of 
characterizing lipophilic/hydrophilic nature of drug. The 
measurement of drug lipophilicity is indication of its 
ability to cross the lipoidal cell membrane
15
. 
Procedure: The partition coefficient study was 
performed using n-octanol as oil phase and phosphate 
buffer pH 7.4 and water as aqueous phase
16
 The two 
phases were mixed in an equal quantity and were 
saturated with each other on a mechanical shaker for 24 
hrs. The saturated phases were separated by separating 
funnel. Equal volume (10 ml each) of the two phases 
were taken in conical flasks and to each, 100 mg of drug 
was added. The flasks were stirred at 320C for 6 hours 
to achieve a complete mixing at 100 rpm. The two 
phases were separated by separating funnel then the 
phases were analyzed for respective drug amount by the 
means of UV spectrophotometer at 210 nm. 
The partition coefficient value “p” was calculated by the 
following equation- 
       
                         
                                        
 
2.1.10. Differential scanning Calorimetry (DSC) : 
Differential scanning Calorimetry, experiments were 
performed with differential Scanning Calorimeter 
chamber
16
. Instrument is comprised of a calorimeter a 
flow controller a thermal analyzer and an operating 
software. Sample of pure Dicycloverine, was weighed in 
an aluminium pan and sealed with an aluminium lid. The 
pan was placed in the DSC and heated from 20-350°C at 
a heating rate of 50°C/min in nitrogen atmosphere. The 
scan was recorded and plotted showing heat flow (w/g) 
on the Y-axis and temperature on the X-axis. 
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2.1.11. Excipients compatibility studies: Fourier 
Transform Infra-Red (FTIR) Spectroscopy
17
 
Interaction of drug with excipients was confirmed by 
carrying out IR interactions studies. Drug and excipients 
used in study were placed in air tight screw cap amber 
colored vials, then vials were kept at room temperature 
as well as in hot air oven at 400C for one week to get 
them moisture free and FT-IR analysis was carried out 
with saturated potassium bromide using pellet making 
method. Standard and KBr were taken in the ratio of 
1:300 to make a solid disc or pellet with the help of 
Hydraulic Pellet Machine. 
2.1.12. Preparation of Calibration Curve: 
Calibration curve of Dicycloverine: - 10 mg of drug 
was weighed and dissolved in 10 ml of phosphate buffer 
6.8, to give a solution of 1000 μg/ml concentration18. 
From this solution 1 ml was taken and diluted to 10ml 
using Phosphate buffer 6.8to produce a stock solution of 
100 μg/ml. From this stock solution different 
concentrations were prepared. The absorbance of these 
solutions was measured at 210 nm by UV 
spectrophotometer. Calibration curve of Dicycloverine 
also prepared in water by preparing stock solution of 
different concentration ranging from 2-16 μg/ml as 
above. The absorbance was measured at 210 nm by UV 
spectrophotometer. 
2.2. Development of floating beads of Dicycloverine 
Hydrochloride by Ionotropic Gelation Method
19
 
The beads of Dicycloverine were prepared by ionotropic 
gelation technique according to the formula given in 
Table 5. 
Accurately weighed drug was added to 100ml of 
Distilled Water and stirred on magnetic stirrer. Polymer, 
CaCO3 and sodium alginate were then added to the 
solution and stir continuously till uniform 
polyelectrolyte solution was formed also known as pre- 
alginate solution. Calcium chloride was separately 
dissolved in 100 ml water and stirred on magnetic 
stirrer. Pre- alginate solution of drug and polymer was 
added drop by drop to the CaCl2 solution with the help 
of 21 G needle. The formed alginate beads were cured at 
different time interval. The alginate beads were there 
after dried overnight at room temperature. 
 
Table 5: Formulation design of floating beads of Dicycloverine Hydrochloride 
Formulation 
code 
Drug  
(mg) 
Sodium  
Alginate (%) 
HPMC 
(K100) mg  
Ethyl  
Cellulose (mg) 
PVP 
(mg) 
CaCl2 
Solution (%) 
CaCo3 
(gm) 
FB1 200 3% 200 _ _ 3 1.5 
FB2 200 4% _ 200 _ 3 1.5 
FB3 200 4% _ _ 200 3 1.5 
FB4 200 3% 100 100 _ 3 1.5 
FB5 200 5% _ 100 100 3 1.5 
FB6 200 2% 100 _ 100 3 1.5 
FB7 200 2% _ _ _ 3 1.5 
 
2.2.1. Evaluation Tests for Floating Beads20, 21 
2.2.2. Particle size analysis: 
The beads should be studied for shape and size for 
uniform    distribution. It can be obtained by various 
techniques given below. 
2.2.3. SEM of floating beads 
 Morphological characterization of the floating beads is 
done by taking scanning electron micrograph (Model 
Jeol JSM-5200)
22
. Cross-sectional views are obtained by 
cutting the bead with a razor blade. The samples were 
coated to 200 Aº thickness with gold- palladium prior to 
microscopy. A working distance of 20 nm, a tilt of 0º 
and accelerating voltage of 15 KV were the operating 
parameters. Photographs were taken within the range of 
50- 500 magnifications. 
2.2.4. Determination of Percentage yield 
The prepared beads were collected and weighed. The 
measured weight was divided by the total amount of all 
non-volatile components, which were used for the 
preparation of the beads. 
                  
                         
                             
       
2.2.5. Drug Entrapment Efficiency 
Beads equivalent to 100 mg of the drug were taken for 
evaluation. The amount of drug entrapped was estimated 
by rushing the beads and extracting with aliquots of 
0.1N HCl repeatedly. The extract was transferred to a 
100 ml volumetric flask and the volume was made up 
using 0.1N 
HCl. The solution was filtered and the absorbance was 
measured at suitable wavelength against appropriate 
blank. The amount of drug entrapped in the beads was 
calculated by the following formula, 
 
                           
 
                                
                                
       
 
2.2.6. In vitro buoyancy study 
Beads (300mg) were spread over the surface of a USP 
XXIV dissolution apparatus type II filled with 900 ml of 
0.1 N HCl containing 0.02% Tween 80. The medium 
was agitated with a paddle rotating at 100 rpm for 12 hr. 
The floating and the settled portions of beads were 
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recovered separately. The beads were dried and 
weighed. Buoyancy percentage was calculated as the 
ratio of the mass of the beads that remained floating and 
the total mass of the beads.  
                
   
         
      
Where, 
 Qf = Weight of the floating Beads  
Qs = Weight of settled Beads 
2.2.7. In-vitro drug release study 
The drug release study from beads is performed using 
USP dissolution apparatus Type I in 900 ml of 0.1 N 
HCl dissolution media (pH- 1.2) at 100 rpm and 37°C. 2 
ml sample was withdrawn at 1 hr. time interval for 12 
hr. and same volume of fresh medium was replaced to 
maintained sink condition. Withdrawn samples were 
assayed spectrophotometrically at suitable wavelength. 
The drug release was analyzed by UV spectro-
photometer. 
2.2.8.  Determination of Moisture Content 
The formulations were subjected to moisture content 
study by using an IR moisture balance by placing the 
beads at 60 °C for 10 min. 
2.2.9. Stability study 
Stability studies of floating beads of Dicycloverine 
HCL
23
 
Stability studies carried out by storing the prepared 
floating beads of Dicycloverine HCL at various 
temperature conditions like refrigeration on (2-80C) 
room temperature (25±0.50C) and elevated temperature 
(45±0.50C) for a period of 12 weeks. Drug content was 
periodically monitored. ICH (International Conference 
on Harmonization) guidelines suggests stability studies 
for floating beads powder meant for reconstitution 
should be studied for accelerated stability at 75% 
relative humidity as per international climatic zones and 
climatic conditions
23
. 
3.  RESULTS AND DISCUSSION 
3.1.  Preformulation Studies 
Preformulation studies were carried out to find out the 
powder properties such as angle of repose, bulk density, 
tapped density and Carr’s index, hausner’s ratio as per 
the methods described in methodology. The results are 
reported in Table 6. 
Table 6: Powder properties of Dicycloverine 
hydrochloride 
S.NO Powder Properties Results 
1.  Angle of repose (θ) 17.43±0.081 
2.  Bulk density (gm/mL) 1.09±0.008 
3.  Tapped Density (gm/mL) 1.38±0.028 
4.  Carr’s Index (%) 20.69±0.35 
5.  Hausner’s Ratio 1.26±0.003 
 
The angle of repose of Dicycloverine HCl was found to 
be in the range of 25
0
 to30
0
 indicates good flow property 
and acceptable characteristics. The % compressibility 
index was determined from the bulk and tapped 
densities. The percentage compressibility index of 
Dicycloverine HCl were found to be in the range of 11 
% to 23%, were also within the acceptable limit. The 
Hausner’s ratio of Dicyclomine HCl was found to be 
near 1.26 indicates good flow properties. 
3.1.1. Physical Appearance: Dicycloverine 
Hydrochloride was found to be white or almost white, 
crystalline powder. 
3.1.2. Solubility: Freely soluble in water, alcohol and 
chloroform but very slightly soluble in ether. 
3.1.3. Melting Point: The melting point of 
Dicycloverine Hydrochloride was found to be 160-
163ºC by capillary tube method. 
3.1.4. Partition Coefficient: Log P value was found to 
be 5.5 
3.1.5. Preparation of Calibration Curve: The 
calibration curve for Dicycloverine HCL was plotted in 
phosphate buffer, pH 6.8 and water .The graphs was 
plotted between concentration (X axis) and absorbance 
(Y-axis). The results of calibration curve of 
Dicycloverine HCL were shown in Figure 1 and 2 
shows the absorbance of Dicycloverine hydrochloride 
standard solution containing 1-6 µg/ml of drug in 
phosphate buffer pH 6.8 and water at the maximum 
wavelength of 210nm. 
 
Figure 1: Standard Curve for Dicycloverine HCL in 
phosphate buffer 6.8 
 
Figure 2: Standard Curve for Dicycloverine HCL in 
Water.
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Figure 3: DSC of Dicycloverine HCL 
 
Figure 4: FTIR spectrum of Dicycloverine HCL 
 
Figure 5: FTIR spectrum of Dicycloverine HCL and HPMCK100 
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Figure 6: FTIR spectrum of Dicycloverine HCL and PVP 
 
Figure 7: FTIR spectrum of Dicycloverine HCL and EC 
 
 
Figure 8: Floating beads formulations of batch FB1 
 
Figure 9: Floating beads formulations of batch FB2 
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Figure 10: Floating beads formulations of batch FB3 
 
Figure 11: Floating beads formulations of batch FB4 
 
Figure 12: Floating beads formulations of batch FB5 
 
 
Figure 13: Floating beads formulations of batch FB6 
 
Figure 14: Floating beads formulations of batch FB7 
 
Figure 15: Scanning Electron Microscopy of floating 
beads of Dicycloverine HCL
Table 7: Characterization of floating beads of Dicycloverine HCL 
Batch Code Yield (%) Entrapment Efficiency (%) % Buoyancy 
FB1 60.34±0.061 90%±0.014 68.23±0.081 
FB2 66.41±0.085 85%±0.021 71.46±0.032 
FB3 65.46±0.102 92.5%±0.07 70.84±0.125 
FB4 90.23±0.043 80.15%±0.20 96.21±0.063 
FB5 74.27±0.042 86.4%±0.34 79.38±0.081 
FB6 78.29±0.120 76.4%±0.036 92.12±0.078 
FB7 80.45±0.091 81%±0.047 78.38±0.032 
(Mean±S.D, N=3) 
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Figure 16: Percentage of drug released from floating 
beads of Dicycloverine HCL of batch FB1 to FB4 
 
 
Figure 17: Percentage of drug released from floating 
beads of Dicycloverine HCL of batch FB5 to FB7
Table 8: Stability Study of floating beads of Dicycloverine HCL Batch FB1 and FB2 
(Mean±S.D, N=3) 
Table 9: Stability Study of floating beads of Dicycloverine HCL Batch FB3 and FB4 
 
Weeks  
Batch FB3 Batch FB4 
Refrigeration 
(4 ±2
O
C) 
Room  
(30±2
O
C) 
Oven  
(40±2
O
C) 
Refrigeration 
(4 ±2
O
C) 
Room 
 (30±2
O
C) 
Oven  
(40±2
O
C) 
0 100 100 100 100 100 100 
1 96.89±0.01 95.72±0.01 95.95±0.15 95.66±0.04 95.46±0.03 95.57±0.13 
3 95.32±0.01 94.84±0.03 95.41 ±0.26 95.03±0.03 94.56±0.01 95.31±0.20 
6 94.43±0.23 94.02±0.15 94.79 ±0.14 94.95±0.14 93.88±0.07 94.94±0.17 
9 93.79±0.11 93.58±0.8 94.09 ±0.28 94.78±0.26 93.69±0.06 94.80±0.22 
12 93.68±0.31 93.23±0.08 93.64 ±0.25 94.56±0.30 93.51±0.09 94.54±0.33 
(Mean±S.D, N=3) 
Table 10: Stability Study of floating beads of Dicycloverine HCL Batch FB5 and FB6 
 
Weeks  
Batch FB5 Batch FB6 
Refrigeration 
(4 ±2
O
C) 
Room  
(30±2
O
C) 
Oven  
(40±2
O
C) 
Refrigeration 
(4 ±2
O
C) 
Room 
 (30±2
O
C) 
Oven  
(40±2
O
C) 
0 100 100 100 100 100 100 
1 96.63±0.01 96.72±0.06 96.63±0.04 95.86±0.04 95.56±0.03 95.77±0.13 
3 95.83±0.03 95.91±0.06 95.71 ±0.09 95.23±0.03 94.38±0.01 95.31±0.20 
6 95.033±0.06 94.45±0.06 94.53±0.13 94.85±0.14 93.95±0.07 94.84±0.17 
9 94.49±0.04 93.68±0.8 93.79 ±0.28 94.78±0.26 93.69±0.06 94.79±0.22 
12 94.38±0.03 93.13±0.03 93.54 ±0.29 94.56±0.30 93.41±0.09 93.54±0.33 
(Mean±S.D, N=3) 
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FB5 
FB6 
FB7 
Weeks Batch FB1 Batch FB2 
Refrigeration 
(4 ±2
O
C) 
Room  
(30±2
O
C) 
Oven  
(40±2
O
C) 
Refrigeration 
(4 ±2
O
C) 
Room 
(30±2
O
C) 
Oven  
(40±2
O
C) 
0 100 100 100 100 100 100 
1 96.10±0.01 95.89±0.01 95.83±0.15 96.5±0.04 96.23±0.03 96.19±0.13 
3 95.62±0.01 94.43±0.03 95.40±0.26 95.53±0.03 94.83±0.01 95.28±0.20 
6 94.10±0.23 94.02±0.15 95.01±0.14 94.92±0.14 94.42±0.07 94.69±0.17 
9 95.00±0.11 94.90±0.8 95.00±0.28 94.26±0.26 93.82±0.06 94.16±0.22 
12 94.64±0.31 94.56±0.08 94.50±0.25 93.88±0.30 93.25±0.09 93.87±0.33 
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Table 11: Stability Study of floating beads of Dicycloverine HCL Batch FB7 
 
Weeks  
Batch FB7 
Refrigeration 
(4 ±2
O
C) 
Room  
(30±2
O
C) 
Oven  
(40±2
O
C) 
0 100 100 100 
1 94.66±0.01 94.26±0.06 94.17±0.04 
3 93.03±0.03 93.56±0.06 93.01 ±0.09 
6 92.45±0.06 92.38±0.06 92.14±0.13 
9 91.78±0.04 91.79±0.8 91.68 ±0.28 
12 90.16±0.03 90.51±0.03 90.04 ±0.29 
(Mean±S.D, N=3) 
CONCLUSION 
The present study has been a satisfactory attempt to 
formulate floating beads with a view of improving oral 
bioavailability and giving a prolonged release of drug. 
The floating beads prepared with HPMC, ethyl cellulose, 
and polyvinyl pyrrolidine were successfully formulated 
into floating beads for oral administration. The polymers 
studied were found to be the efficient carriers for 
Dicycloverine beads showing controlled release. The 
floating systems have been found to have good potential 
for prolonged drug release and therefore can be 
beneficial for use in the treatment of various GIT 
disorders. Additional benefits such as dose reduction, 
reduced frequency of administration and avoiding 
related systemic side effects can be produced.
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